[go: up one dir, main page]

ZA987591B - Vaccine. - Google Patents

Vaccine.

Info

Publication number
ZA987591B
ZA987591B ZA9807591A ZA987591A ZA987591B ZA 987591 B ZA987591 B ZA 987591B ZA 9807591 A ZA9807591 A ZA 9807591A ZA 987591 A ZA987591 A ZA 987591A ZA 987591 B ZA987591 B ZA 987591B
Authority
ZA
South Africa
Prior art keywords
protein
relates
human
provides
vaccine
Prior art date
Application number
ZA9807591A
Other languages
English (en)
Inventor
Claudine Bruck
Teresa Cabezon Silva
Anne-Marie Eva Fernand Delisse
Catherine Marie Ghislai Gerard
Angela Lombardo-Bencheikh
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ZA987591B publication Critical patent/ZA987591B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ZA9807591A 1997-08-22 1998-08-21 Vaccine. ZA987591B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9717953.5A GB9717953D0 (en) 1997-08-22 1997-08-22 Vaccine

Publications (1)

Publication Number Publication Date
ZA987591B true ZA987591B (en) 2000-02-21

Family

ID=10817971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9807591A ZA987591B (en) 1997-08-22 1998-08-21 Vaccine.

Country Status (23)

Country Link
US (2) US6342224B1 (xx)
EP (1) EP1007551B1 (xx)
JP (1) JP2001513986A (xx)
KR (1) KR20010023193A (xx)
CN (1) CN1276833A (xx)
AT (1) ATE267211T1 (xx)
AU (1) AU732946B2 (xx)
BR (1) BR9812139A (xx)
CA (1) CA2301920C (xx)
CO (1) CO4810234A1 (xx)
DE (1) DE69824013T2 (xx)
ES (1) ES2221198T3 (xx)
GB (1) GB9717953D0 (xx)
HU (1) HUP0004327A3 (xx)
IL (1) IL134392A0 (xx)
MA (1) MA24638A1 (xx)
NO (1) NO20000850L (xx)
NZ (1) NZ502632A (xx)
PL (1) PL339009A1 (xx)
TR (1) TR200000480T2 (xx)
UY (1) UY25146A1 (xx)
WO (1) WO1999010375A2 (xx)
ZA (1) ZA987591B (xx)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
NZ504214A (en) * 1997-10-24 2003-06-30 Invitrogen Corp Recombination cloning using nucleic acids having recombination sites
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
ID28387A (id) * 1998-10-05 2001-05-17 M & E Biotech As Metoda baru untuk vaksinasi terapeutik
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000069456A2 (en) * 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
JP2004501648A (ja) * 2000-06-26 2004-01-22 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム チオレドキシンおよび目的のポリペプチドの間に融合するユビキチンを含む三重融合タンパク質
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
DE60126737T2 (de) 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
WO2003039595A2 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
FR2839080B1 (fr) * 2003-04-03 2007-09-28 Neovacs Procede de preparation d'un produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, par des cellules de la levure pichia pastoris
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
PL220107B1 (pl) 2002-08-02 2015-08-31 Glaxosmithkline Biolog Sa Preparat immunogenny, szczepionka oraz zastosowanie tej szczepionki
AR041086A1 (es) * 2002-08-30 2005-04-27 Glaxo Group Ltd Vacuna
AU2003282731B2 (en) * 2002-10-03 2009-01-08 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
DK1556477T3 (en) 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
TWI315986B (en) * 2002-11-07 2009-10-21 Synergy America Inc Compositions and methods for treating or preventing pneumococcal infection
EP1608767B1 (en) * 2003-03-24 2012-02-22 Merck Sharp & Dohme Corp. Optimized expression of hpv 31 l1 in yeast
CZ297389B6 (cs) * 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
ES2346314T3 (es) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
EP1697534B1 (en) * 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US10941353B2 (en) * 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
PL1753846T3 (pl) 2004-04-28 2016-12-30 Sposoby i układy obróbki wodorem w złożu ebulującym
MX274369B (es) * 2004-04-28 2010-03-05 Headwaters Heavy Oil Llc Metodos y sistemas de hidroprocesamiento de lecho fijo y metodos para mejorar un sistema de lecho fijo existente.
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
PT1896061T (pt) 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Composição imunogénica
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2594576B1 (en) * 2006-07-28 2015-07-01 The Trustees of The University of Pennsylvania Improved HIV vaccines
ES2764222T3 (es) * 2006-09-08 2020-06-02 Wyeth Llc Lavado con arginina en la purificación de proteínas mediante el uso de cromatografía de afinidad
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
ES2393812T3 (es) * 2007-01-15 2012-12-28 Glaxosmithkline Biologicals Sa Vacuna
US8034232B2 (en) * 2007-10-31 2011-10-11 Headwaters Technology Innovation, Llc Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8142645B2 (en) * 2008-01-03 2012-03-27 Headwaters Technology Innovation, Llc Process for increasing the mono-aromatic content of polynuclear-aromatic-containing feedstocks
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
JP2013521326A (ja) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CN103180343B (zh) 2010-08-13 2016-01-20 株式会社吉耐森 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
EP2806889B1 (en) 2012-01-24 2017-08-16 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
EP2968527A4 (en) 2013-03-12 2016-08-17 Univ Pennsylvania IMPROVED VACCINES AGAINST HUMAN PAPILLOMA VIRUS AND METHOD FOR USE THEREOF
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
US11135262B2 (en) 2014-08-15 2021-10-05 Genexine, Inc. Methods of treating cervical cancer
EP3212778B1 (en) 2014-10-28 2019-08-28 Agrivida, Inc. Methods and compositions for stabilizing trans-splicing intein modified proteases
WO2016090540A1 (zh) * 2014-12-08 2016-06-16 刘日廷 人乳头瘤病毒(hpv)18型致癌性e6和e7蛋白的抗原表位最小基序肽
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
TWI670280B (zh) * 2016-02-23 2019-09-01 財團法人國家衛生研究院 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
JP7336831B2 (ja) 2017-03-02 2023-09-01 ハイドロカーボン テクノロジー アンド イノベーション、エルエルシー ファウリングが少ない堆積物を伴う改良された沸騰床リアクター
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
CN115551547A (zh) 2020-04-24 2022-12-30 格纳西尼有限公司 宫颈癌治疗方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
DE4015044A1 (de) 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
CN1067382A (zh) * 1990-09-26 1992-12-30 布里斯托尔-迈尔斯斯奎尔公司 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
DE4441197C1 (de) * 1994-11-18 1996-03-28 Deutsches Krebsforsch Expressionsplasmide für Hefe
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5958750A (en) * 1996-07-03 1999-09-28 Inctye Pharmaceuticals, Inc. Human hyaluronidase

Also Published As

Publication number Publication date
US20020182221A1 (en) 2002-12-05
TR200000480T2 (tr) 2000-07-21
AU9263998A (en) 1999-03-16
HUP0004327A3 (en) 2003-08-28
UY25146A1 (es) 2000-12-29
BR9812139A (pt) 2000-07-18
AU732946B2 (en) 2001-05-03
WO1999010375A3 (en) 1999-06-10
NO20000850D0 (no) 2000-02-21
MA24638A1 (fr) 1999-04-01
NO20000850L (no) 2000-04-14
ATE267211T1 (de) 2004-06-15
DE69824013T2 (de) 2005-06-02
ES2221198T3 (es) 2004-12-16
CO4810234A1 (es) 1999-06-30
US6342224B1 (en) 2002-01-29
EP1007551A2 (en) 2000-06-14
CN1276833A (zh) 2000-12-13
PL339009A1 (en) 2000-12-04
IL134392A0 (en) 2001-04-30
GB9717953D0 (en) 1997-10-29
CA2301920A1 (en) 1999-03-04
CA2301920C (en) 2011-01-04
JP2001513986A (ja) 2001-09-11
NZ502632A (en) 2002-03-28
WO1999010375A2 (en) 1999-03-04
HUP0004327A1 (en) 2001-03-28
DE69824013D1 (de) 2004-06-24
KR20010023193A (ko) 2001-03-26
EP1007551B1 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
GB9717953D0 (en) Vaccine
BR9814487A (pt) "vacina"
DE69834671D1 (de) Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
EP0759935A4 (en) RECOMBINANT PAPILLOMAVIRUS L1
DE69535018D1 (de) Papillomavirus vakzine
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
GR3023297T3 (en) Ehv-4 glycoprotein vaccine
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
HUP9904137A2 (hu) Immunterápiás szerként hasznosítható polipeptidek és eljárások a polipeptidek előállítására
EP1336621A3 (en) Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins